1 Srivastava JK, Shankar E, Gupta S. Chamomile: A herbal medicine of the past with bright future. Mol Med Rep. 2010; 3(6):895-901.
EMA/HMPC/55837/2011. Committee on Herbal Medicinal Products (HMPC). Assessment report on Matricaria recutita L., flos and Matricaria recutita L., aetheroleum.
Gerritsen ME, Carley WW, Ranges GE-, et al. Flavonoids inhibit cytokine-induced endothelial cell adhesion protein gene expression. Am J Pathol. 1995; 147(2):278-292.
Bigagli E, Cinci L, D'Ambrosio M, Luceri C. Pharmacological activities of an eye drop containing Matricaria chamomilla and Euphrasia officinalis extracts in UVB-induced oxidative stress and inflammation of human corneal cells. J Photochem Photobiol B. 2017 Aug;173:618-625.
Nissen HP, Biltz H, Kreysel HW. Profilometrie, eine Methode zur Beurteilung der therapeutischen Wirksamkeit von Kamillosan-Salbe. Z Hautkr 1988, 63:184-190
Korting HC, Schäfer-Korting M, Hart H, Laux P, Schmid M. Anti-inflammatory activity of hamamelis distillate applied topically to the skin. Influence of vehicle and dose. Eur J Clin Pharmacol. 1993; 44(4):315-8
2 EMA/HMPC/246799/2009. Committee on Herbal Medicinal Products (HMPC) Assessment report on Euphrasia officinalis L. and Euphrasia rostkoviana Hayne, herba. 16 September 2010
Teixeira R., Silva L.R. Bioactive compounds and in vitro biological activity of rostkoviana Hayne extracts. Ind. Crops Prod., 2013, 50, 680– 689.
Сер and Хімія. Euphrasia rostkoviana hayne-active components and biological activity for the treatment of eye disorders. 2017.
Paduch R, Woźniak A, Niedziela P, Rejdak R. Assessment of eyebright (euphrasia officinalis L.) extract activity in relation to human corneal cells using in vitro tests. Balkan Med J. 2014 Mar;31(1):29-36.
Liu Y, Hwang E, Ngo HTT, Perumalsamy H, Kim YJ, Li L, Yi TH. Protective Effects of Euphrasia officinalis Extract against Ultraviolet B-Induced Photoaging in Normal Human Dermal Fibroblasts. Int J Mol Sci. 2018 Oct 25;19(11):3327.
Bielory L, Heimall J. Review of complementary and alternative medicine in treatment of ocular allergies. Curr Opin Allergy Clin Immunol. 2003 Oct;3(5):395-9.
Stoss M, Michels C, Peter E, Beutke R, Gorter RW. Prospective cohort trial of Euphrasia single-dose eye drops in conjunctivitis. J Altern Complement Med. 2000 Dec;6(6):499-508.
Stoffel L, Zimmermann D, Hunkeler R, Zimmermann C, Ramos M, Fathi-Torriani M, et al. Euphrasia-Augentropfen bei Neugeborenen: Ein Pilotprojekt. Schweiz Zschr Ganzheitsmedizin. (2007) 19:254–9.
Meier-Girard D, Gerstenberg G, Stoffel L, Kohler T, Klein SD, Eschenmoser M, Mitter VR, Nelle M, Wolf U. Euphrasia Eye Drops in Preterm Neonates With Ocular Discharge: A Randomized Double-Blind Placebo-Controlled Trial. Front Pediatr. 2020 Aug 11;8:449.
3 EMA/HMPC/603409/2017 Committee on Herbal Medicinal Products (HMPC). Assessment report on Calendula officinalis L., flos. 27 March 2018
Efstratiou E, Hussain AI, Nigam PS, Moore JE, Ayub MA, Rao JR. Antimicrobial activity of Calendula officinalis petal extracts against fungi, as well as Gram-negative and Gram-positive clinical pathogens. Complement Ther Clin Pract. 2012 Aug; 18(3):173-6.
Akhtar N, Zaman SU, Khan BA, Amir MN, Ebrahimzadeh MA. Calendula extract: effects on mechanical parameters of human skin. Acta Pol Pharm. 2011 Sep-Oct; 68(5):693-701.
Alnuqaydan AM, Lenehan CE, Hughes RR, Sanderson BJ. Extracts from Calendula officinalis offer in vitro protection against H2 O2 induced oxidative stress cell killing of human skin cells. Phytother Res. 2015 Jan; 29(1):120-4.
Nicolaus C, Junghanns S, Hartmann A, Murillo R, Ganzera M, Merfort I. In vitro studies to evaluate the wound healing properties of Calendula officinalis extracts. J Ethnopharmacol. 2017 Jan 20; 196:94-103.